Effect of perinatal antiretroviral drug exposure on hematologic values in HIV-uninfected children: An analysis of the women and infants transmission study

Journal of Infectious Diseases

Volumn 194, Issue 8, 2006, Pages 1089-1097

  Pacheco, Susan E ^a   McIntosh, Kenneth ^b   Lu, Ming ^c   Mofenson, Lynne M ^d   Diaz, Clemente ^e   Foca, Marc ^f   Frederick, Margaret ^c   Handelsman, Edward ^g   Hayani, Karen ^h   Shearer, William T ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c Clinical Trials & Surveys Corp   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^e UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^f New York Presbyterian Hospital Columbia University Medical Center   (United States)

^g SUNY DOWNSTATE MEDICAL CENTER   (United States)

^h UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; HEMOGLOBIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; BLOOD ANALYSIS; CD4 LYMPHOCYTE COUNT; CHILD; CONTROLLED STUDY; DISEASE TRANSMISSION; FEMALE; FOLLOW UP; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTIVARIATE ANALYSIS; NEUTROPHIL COUNT; NEWBORN; NONHUMAN; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; THROMBOCYTE COUNT; VERTICAL TRANSMISSION;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD CELL COUNT; BLOOD PLATELETS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; DISEASE TRANSMISSION, VERTICAL; FEMALE; HEMOGLOBINS; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; NEUTROPHILS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 33749596526     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/507645     Document Type: Article

References (29)

1. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331:1173-80.
2. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002; 29:484-94.
3. Centers for Disease Control. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. Available at: http://AIDSInfo.nih.gov. Accessed 25 November 2005.
4. Chotpitayasunondh T, Vanprapar N, Simonds RJ, et al. Safety of late in utero exposure to zidovudine in infants born to human immunodeficiency virus-infected mothers: Bangkok. Bangkok Collaborative Perinatal HIV Transmission Study Group. Pediatrics 2001; 107:E5.
5. Culnane M, Fowler M, Lee SS, et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. JAMA 1999; 281:151-7.
6. Mofenson LM, Munderi P. Safety of antiretroviral prophylaxis of perinatal transmission for HIV-infected pregnant women and their infants. J Acquir Immune Defic Syndr 2002; 30:200-15.
7. Dagan T, Sable C, Bray I, Gerschenson M. Mitochondria] dysfunction and antiretroviral nucleoside analog toxicities: what is the evidence? Mitochondrion 2002; 1:397-412.
8. Kamemoto LE, Shiramizu B, Gerschenson M. HIV-associatcd mitochondrial toxicity in pregnancy. Mitochondrion 2004; 4:153-62.
9. Barret B, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS 2003; 17:1769-85.
10. Landreau-Mascaro A, Barret B, Mayaux MJ, Tardieu M, Blanche S. Risk of early febrile seizure with perinatal exposure to nucleoside analogues. Lancet 2002; 359:583-4.
11. Le Chenadec I, Mayaux MJ, Guihenneuc-Jouyaux C, Blanche S. Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants. AIDS 2003; 17:2053-61.
12. The Perinatal Safety Review Working Group. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. J Acquir Immune Defic Syndr 2000; 25:261-8.
13. European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr 2003; 32:380-7.
14. European Collaborative Study. Levels and patterns of neutrophil cell counts over the first 8 years of life in children of HIV-1-infected mothers. AIDS 2004; 18:2009-17.
15. Bunders M, Thorne C, Newell ML. Maternal and infant factors and lymphocyte, CD4 and CD8 cell counts in uninfected children of HIV-1-infected mothers. AIDS 2005; 19:1071-9.
16. Calvelli T, Denny TN, Paxton H, Gelman R, Kagan I. Guideline for flow cytometric immunophenotyping: a report from the National Institute of Allergy and Infectious Diseases, Division of AIDS. Cytometry 1993; 14:702-15.
17. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med 1999; 341:394-402.
18. Rodriguez EM, Mofenson LM, Chang BH, et al. Association of maternal drug use during pregnancy with maternal HIV culture positivity and perinatal HIV transmission. AIDS 1996; 10:273-82.
19. Bunders MJ, Bekker V, Scherpbier HJ, Boer K, Godfried M, Kuijpers TW. Haematological parameters of HIV-1-uninfected infants born to HIV-1-infected mothers. Acta Paediatr 2005; 94:1571-7.
20. Chitnis S, Mondal D, Agrawal KC. Zidovudine (AZT) treatment suppresses granulocyte-monocyte colony stimulating factor receptor type alpha (GM-CSFR alpha) gene expression in murine bone marrow cells. Life Sci 2002; 71:967-78.
21. Dainiak N, Worthington M, Riordan MA, Kreczko S, Goldman L. 3′-Azido-3′-deoxythymidine (AZT) inhibits proliferation in vitro of human haematopoietic progenitor cells. Br J Haematol 1988; 69:299-304.
22. Lewis LD, Amin S, Civin CI, Lietman PS. Ex vivo zidovudine (AZT) treatment of CD34+ bone marrow progenitors causes decreased steady state mitochondrial DNA (mtDNA) and increased lactate production. Hum Exp Toxicol 2004; 23:173-85.
23. Setzer B, Schlesier M, Thomas AK, Walker UA. Mitochondrial toxicity of nucleoside analogues in primary human lymphocytes. Antivir Ther 2005; 10:327-34.
24. Setzer B, Schlesier M, Walker UA. Effects of didanosine-related depletion of mtDNA in human T lymphocytes. J Infect Dis 2005; 191:848-55.
25. Shah MM, Li Y, Christensen RD. Effects of perinatal zidovudine on hematopoiesis: a comparison of effects on progenitors from human fetuses versus mothers. AIDS 1996; 10:1239-47.
26. Poirier MC, Divi RL, Al-Harthi L, et al. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J Acquir Immune Defic Syndr 2003; 33:175-83.
27. Gesner M, Papaevangelou V, Kim M, et al. Alteration in the proportion of CD4 T lymphocytes in a subgroup of human immunodeficiency virus-exposed- uninfected children. Pediatrics 1994; 93:624-30.
28. Holt PG, Jones CA. The development of the immune system during pregnancy and early life. Allergy 2000; 55:688-97.
29. West LJ. Defining critical windows in the development of the human immune system. Hum Exp Toxicol 2002; 21:499-505.